USC Norris Comprehensive Cancer Center | Strategic Alliance Partners

This case demonstrates the pivotal role of a cohesive multidisciplinary team in navigating the complex care of oncology patients from diagnosis, treatment, and posttreatment surveillance.

Entrectinib elicited encouraging responses in patients with breast cancer that harbors NTRK fusions, according to updates from the phase 2 STARTRK-2 trial.

Event co-chair, Syma Iqbal, MD, discusses key points from a recent OncLive® Institutional Perspectives in Cancer webinar, which focused on the evolving landscapes in gastrointestinal cancer.

The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.

Germline variation may cause men of African descent to have a higher risk of prostate than men of European descent.

Although pancreatic cancer has been a historically difficult disease to treat, the emergence of novel combinations have allowed for more patients to receive later lines of therapy, and recent advances have inspired a shift to more personalized treatment approaches to improve outcomes, according to Syma Iqbal, MD.